Kazinol U may have therapeutic value in delaying pancreatic β-cell destruction in type 1 diabetes by blocking the NF-κB pathway in pancreatic β-cells reduces cell damage. Kazinol U shows estrogenic activity with ligand-activity of estrogen receptor, transcriptional activity of estrogen -responsive element-reporter genes, it may have beneficial effects in the treatment of menopausal symptoms.
Broussoflavonol F has antiplatelet effect, is partially due to an inhibitory effect on cyclooxygenase, can inhibit arachidonic acid (AA)-induced platelet aggregation. Broussoflavonol F shows inhibitory activities on mushroom tyrosinase. Broussoflavonol F
5,7,3',4'-Tetrahydroxy-3-methoxy-8,5'-diprenylflavone demonstrated a strong anti-proliferative effect on ER-positive breast cancer MCF-7 cells in vitro, with an IC50 value of 4.41 μM. It significantly down-regulated the expression of estrogen receptor-α (ER-α) and inhibited tumor growth in the BCAP-37 human breast cancer cell line xenograft model.
7,3'-Dihydroxy-4'-methoxyflavan is a natural product of Broussonetia, Moraceae. The catalog number is TN3211 and the CAS number is 162290-05-3. 7,3'-Dihydroxy-4'-methoxyflavan can be used as a reference standard.
Kazinol A shows strong inhibition of arachidonic acid (AA)-induced platelet aggregation. It also exhibits potent inhibition with IC50 values ranging 0.6-164 M against XOD. Kazinol A may be a candidate for the development of effective anti-cancer drug on h
Broussonins A and B, new phytoalexins from diseased paper mulberry. Broussonin B can induce neurite outgrowth in PC-12 cells at concentration of 50 microg/ml, and show moderate inhibitory activities against a chymotrypsin-like activity of the proteasome.B
Broussonins A and B, new phytoalexins from diseased paper mulberry. Broussonin A shows estrogenic activity with ligand-binding activity of estrogen receptor, transcriptional activity of estrogen-responsive element-luciferase reporter genes. Broussonin A c
Broussonin E could suppress inflammation by modulating macrophages activation state via inhibiting the ERK and p38 MAPK and enhancing JAK2-STAT3 signaling pathway, and can be further developed as a promising drug for the treatment of inflammation-related